A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Completed · Phase 2
Conditions studied: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
In brief
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
Key facts
- Study ID
- NCT01421472
- Run by
- Merrimack Pharmaceuticals
- People needed
- 196
- Starts
- 2011-08-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2016-05-03
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Histological confirmation of ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2)
- Free of metastatic disease
- ≥ 18 years old
- Female
- Had no prior treatment for any cancer
- Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide
You may not qualify if…
- Have a history of severe allergic reactions to paclitaxel or other drugs formulated in Cremaphor® EL
- Are pregnant or breastfeeding
Where it is running
- Universito of Birmingham atAlabama — Birmingham, Alabama, United States
- Arizona Oncology Associates — Tucson, Arizona, United States
- Arizona Oncology Associates — Tuscon, Arizona, United States
- Marin Cancer Center — Greenbrae, California, United States
- PMK Medical Group — Oxnard, California, United States
- Wilshire Oncology Medical Group — Rancho Cucamonga, California, United States
- Florida Cancer Research Institute — Plantation, Florida, United States
- Piedmont Healthcare — Altanta, Georgia, United States
- Piedmont Fayette Hospital — Fayetteville, Georgia, United States
- Georgia Cancer Specialists — Marietta, Georgia, United States
- University Of Chicago — Chicago, Illinois, United States
- Illinois Cancer Specialists — Niles, Illinois, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Beaumont Health Systems — Royal Oak, Michigan, United States
- Comprehensive Cancer Centers of Nevada — Henderson, Nevada, United States
- Cooper Cancer Institute — Voorhees Township, New Jersey, United States
- University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
- Memorial Medical Center — Las Cruces, New Mexico, United States
- Northwest Cancer Specialists — Portland, Oregon, United States
- Cancer Center of the Carolinas — Greenville, South Carolina, United States
- Texas Oncology - Amarillo — Amarillo, Texas, United States
- Texas Oncology-Austin Central — Austin, Texas, United States
- Texas Oncology - Bedford — Bedford, Texas, United States
- Texas Oncology - Medical City — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.